Page 65 - MemoriaEHD-Eng

www.ciberehd.org

• C MJ, C M, D e, B- a M, B F, i e. Safety
Most relevant asaNovahaparrooMèNeCharreiroDeCostaerMeJogLesias
of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory
scientific bowel disease.Am J Gastroenterol. 2013 Mar;108(3):433-40.

articles
• guarDioLa J, garCía-igLesias p, roDríguez-MoraNta F, BruLLet e, saLo J, aLBa e. [Manage-
ment of acute lower gastrointestinal hemorrhage: position statement of the Catalan

Society of Gastroenterology].Gastroenterol Hepatol. 2013 Oct;36(8):534-45.

• MegrauD F, CoeNeN s, versporteN a, Kist M, López-Brea M, hirsChL aM. Helicobacter pylori
resistance to antibiotics in Europe and its relationship to antibiotic consumption.Gut.

2013 Jan;62(1):34-42.

• saNDBorN WJ, FeagaN Bg, rutgeerts p, haNauer s, CoLoMBeL JF, saNDs Be. Vedolizumab
as induction and maintenance therapy for Crohn’s disease.N Engl J Med. 2013 Aug

22;369(8):711-21.

• gisBert Jp, CaLvet x, BerMeJo F, BoixeDa D, Bory F, BuJaNDa L. [III Spanish Consen-
sus Conference on Helicobacter pylori infection].Gastroenterol Hepatol. 2013

May;36(5):340-74.

ó

•
Highlights
Has been developed the patent: container and method of storing and the extem-
poraneous reconstitution of a mixture of compounds in fixed proportions. Inven-

tors: Caridad Pontes and Xavier Calvet. Patent No.:13382229.6-1651.Date of is- í
sue: 18/06/2013. European patent.

• Have been initiated new collaborative projects for the Helicobacter pylori treatment

and several systematic reviews and studies on quality aspects, social and labor of
inflammatory bowel disease, which are at different stages of development.
ñ
• Has initiated an innovation project about presentations with multiple drugs for the

H. pylori infection treatment in children.
•
Participation in multiple national and international clinical trials.
á
HAVE OBTAINED THE FOLLOWING GRANTS:

• 1007/C/2013. “Novel technologies as non invasive tools for prognosis / diagnosis

of gastric cancer”. Patronat de la Fundació la Marató de TV3. PI: Xavier Calvet. No.
Scientists: 5. Coordinated study composed by three centers (Hospital de Sabadell,

Department of Microbiology of the Faculty of Pharmacy and LEITAT UAB). The aim

is to identify biomarkers of progression to gastric cancer in patients with H. pylori
infection by means of the use of noninvasive technologies (circulating miRNA and í

plasma metabolomics) for the identification and pre-validation of these markers in
blood.
é
FIS-PI10-01203 “Follow-up study on factors associated with progression of preneo-

plastic lesions of gastric cancer”: coordinated Spanish follow-up study. This is a
national project led by Dr. Gonzlez-Svatetz. The project enrolls patients from 14 í

hospitals and has 3 analytical sub-projects: analysis of human genetic (C.Gonzalez-
Svatetz, ICO), epigenetic (M.Esteller, Idibell) and H. pylori virulence factors (X. 13
20
Calvet, Parc Taul).
T
OR
• Fundacin Mutua Madrilea. “Cell Study to gastric cancer progression induced by P
Helicobacter pylori”. Principal Investigator: Mara Jos Ramrez.
RE
L
Other grants:
A
NU
• SAF-2012-39948 “Identification of metabolomic biomarkers for the noninvasive N
A
diagnosis of digestive pathologies related to Helicobacter pylori infection.
D /
• H
FIS-P12-01802 “Evaluation of non-coding RNAs as non-invasive biomarkers of pre- E
cancerous gastric lesions in patients infected with Helicobacter pylori.”
ER
IB
C

65